Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma

Caron Jacobson, Nadja Kopp, Jacob V. Layer, Robert A. Redd, Sebastian Tschuri, Sarah Haebe, Diederik van Bodegom, Liat Bird, Amanda L. Christie, Alexandra Christodoulou, Amy Saur, Trevor Tivey, Stefanie Zapf, Deepak Bararia, Ursula Zimber-Strobl, Scott J. Rodig, Oliver Weigert, David M. Weinstock

Blood (2016) 128 (21): 2517–2526.

https://doi.org/10.1182/blood-2016-04-711176

Published: 2016

Includes: Supplemental data

Journal Articles

Phenotypic and Transcriptional Characterization of Non-Hodgkin Lymphomas from Malawi Defines Targetable Disease Subsets

Elizabeth A. Morgan, MD, M. Patrick Sweeney, Tamiwe Tomoka, MD, Nadja Kopp, M.S., Robert A Redd, MS, Christopher Daniel Carey, MD,, Leo Masamba, MD, Steve Kamiza, MD, Geraldine S Pinkus, MD, Donna S. Neuberg, Sc.D., Scott J. Rodig, MD, PhD, Danny A. Milner, Jr., MD, M.Sc., David M. Weinstock, MD

Blood (2015) 126 (23): 2655.

https://doi.org/10.1182/blood.V126.23.2655.2655

Published: 2015

Journal Articles

B and T-Cell Lymphoma Patient-Derived Xenografts Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development

Blood (2015) 126 (23): 4001.

https://doi.org/10.1182/blood.V126.23.4001.4001

Published: 2015

Journal Articles

The MDM2 Inhibitor NVP-CGM097 Is Highly Active in a Randomized Preclinical Trial of B-Cell Acute Lymphoblastic Leukemia Patient Derived Xenografts

Elizabeth C Townsend, PhD, Tiffany DeSouza, B.S., Mark A. Murakami, MD MA, Joan Montero, PhD, Kristen Stevenson, MS, Amanda L Christie, B.S., Alexandra N Christodolou, M.Sc., Una Vojinovic, B.S., Nadja Kopp, M.S., Patrizia Barzaghi-Rinaudo, Masato Murakami, MD, PhD, Anthony Letai, MD PhD, Sebastien Jeay, Jens Wuerthner, Ensar Halilovic, David M. Weinstock

Blood (2015) 126 (23): 797.

https://doi.org/10.1182/blood.V126.23.797.797

Published: 2015

Journal Articles

Clonal Evolution in Relapsed or Refractory Diffuse Large B Cell Lymphoma

Thomas Melchardt, MD, Clemens Hufnagl, MSC, Oliver Weigert, MD, David M. Weinstock, MD, Nadja Kopp, MA, Lukas Weiss, MD PhD, Daniel Neureiter, MD, Wolfgang Tränkenschuh, MD, Hubert Hackl, Dr, Richard Greil, MD, Alexander Egle, MD

Blood (2014) 124 (21): 77.

https://doi.org/10.1182/blood.V124.21.77.77

Published: 2014

Journal Articles

Type II JAK2 Inhibitor NVP-CHZ868 Is Active in Vivo Against JAK2-Dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs)

Blood (2014) 124 (21): 3713.

https://doi.org/10.1182/blood.V124.21.3713.3713

Published: 2014

Journal Articles

Newer-Generation HSP90 Inhibitors Can Overcome Ibrutinib Resistance and Suppress Proliferation in Human Mantle Cell Lymphoma in Vitro and in Vivo

Nadja Kopp, MA, Sebastian Tschuri, Sarah Haebe, Diederik van Bodegom, PhD, Liat Bird, Amanda L. Christie, Amy Saur, Alexandra N. Christodoulou, Trevor Tivey, Andrew L Kung, MD PhD, Oliver Weigert, MD, David Weinstock, MD

Blood (2014) 124 (21): 1686.

https://doi.org/10.1182/blood.V124.21.1686.1686

Published: 2014

Journal Articles

GNB1 Activating Mutations Promote Myeloid and Lymphoid Neoplasms Targetable By Combined PI3K/mTOR Inhibition

Blood (2014) 124 (21): 3567.

https://doi.org/10.1182/blood.V124.21.3567.3567

Published: 2014

Journal Articles

A targeted mutational landscape of angioimmunoblastic T-cell lymphoma

Blood (2014) 123 (9): 1293–1296.

https://doi.org/10.1182/blood-2013-10-531509

Published: 2014

Includes: Supplemental data

Journal Articles

JAK2 L884P Mutation Confers Resistance To The Type II JAK2 Inhibitor NVP-BBT594 When Co-Occurring With JAK2 R683G But Not JAK2 V617F

Nadja Kopp, Jordy C. Van der Zwet, Jacob Layer, Oliver Weigert, Eric Vangrevelinghe, Akinori Yoda, PhD, Thomas Radimerski, PhD, David Weinstock, MD

Blood (2013) 122 (21): 1429.

https://doi.org/10.1182/blood.V122.21.1429.1429

Published: 2013

Journal Articles

The Beta-Subunit Of Heterotrimeric G Proteins Harbors Gain-Of-Function Mutations In Multiple Hematologic Malignancies

Akinori Yoda, PhD, Guillaume Adelmant, PhD, Nobuaki Shindoh, PhD, Bjoern Chapuy, MD, PhD, Yuka Yoda, MPh, Oliver Weigert, Nadja Kopp, Shuo-Chieh Wu, Sunhee S. Kim, Huiyun Liu, Trevor Tivey, Jeffrey W. Tyner, Jason Gotlib, MD, MS, Michael W. Deininger, MD, PhD, Shannon Turley, PhD, Jarrod A Marto, PhD, Andrew A. Lane, MD, PhD, David M. Weinstock, MD

Blood (2013) 122 (21): 2510.

https://doi.org/10.1182/blood.V122.21.2510.2510

Published: 2013

Journal Articles

Loss-Of-Function Mutations In The Splicing Factor ZRSR2 Are Common In Blastic Plasmacytoid Dendritic Cell Neoplasm and Have Male Predominance

Blood (2013) 122 (21): 741.

https://doi.org/10.1182/blood.V122.21.741.741

Published: 2013

Journal Articles

A Targeted Mutational Landscape of Angioimmunoblastic T-Cell Lymphoma: Association Between Advanced Age and Mutations in TET2 and DNMT3A

Oliver Weigert, MD, Nadja Kopp, Sudha Bolla, MD, Oreofe Odejide, MD, Dan Toscano, Matthew A Lunning, DO, Julie Teruya-Feldstein, MD, Abner Louissaint, MD, PhD, Scott J. Rodig, MD, PhD, Steven M. Horwitz, MD, David Weinstock, MD

Blood (2012) 120 (21): 299.

https://doi.org/10.1182/blood.V120.21.299.299

Published: 2012

Journal Articles

Newer-Generation HSP90 Inhibitors Have Potent Activity Against Human Mantle Cell Lymphoma in Vitro and in Vivo

Oliver Weigert, MD, Diederik van Bodegom, PhD, Liat Bird, Amy Saur, Trevor Tivey, Nadja Kopp, Andrew L. Kung, MD, PhD, David Weinstock, MD

Blood (2012) 120 (21): 1651.

https://doi.org/10.1182/blood.V120.21.1651.1651

Published: 2012

Journal Articles

BET Bromodomain Inhibition Targets Both c-Myc and IL7R in Acute Lymphoblastic Leukemia

Nadja Kopp, Christopher J. Ott, PhD, Liat Bird, Ronald Paranal, Jun Qi, PhD, Teresa Bowman, Scott J. Rodig, MD, PhD, Andrew L. Kung, MD, PhD, James E. Bradner, MD, David Weinstock, MD

Blood (2012) 120 (21): 672.

https://doi.org/10.1182/blood.V120.21.672.672

Published: 2012

Journal Articles

BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia

Christopher J. Ott, Nadja Kopp, Liat Bird, Ronald M. Paranal, Jun Qi, Teresa Bowman, Scott J. Rodig, Andrew L. Kung, James E. Bradner, David M. Weinstock

Blood (2012) 120 (14): 2843–2852.

https://doi.org/10.1182/blood-2012-02-413021

Published: 2012

Includes: Supplemental data

Journal Articles

Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2

Diederik van Bodegom, Jun Zhong, Nadja Kopp, Chaitali Dutta, Min-Sik Kim, Liat Bird, Oliver Weigert, Jeffrey Tyner, Akhilesh Pandey, Akinori Yoda, David M. Weinstock

Blood (2012) 120 (14): 2853–2863.

https://doi.org/10.1182/blood-2012-02-413252

Published: 2012

Includes: Supplemental data

Journal Articles

Molecular Ontogeny of Donor-Derived Lymphomas Occurring After Transplantation,

Oliver Weigert, MD, Nadja Kopp, Andrew A. Lane, MD, PhD, Akinori Yoda, PhD, Suzanne E. Dahlberg, PhD, Donna Neuberg, ScD, Anita Y Bahar, Bjoern Chapuy, MD, PhD, Frank Kuo, MD, PhD, Terry Haley, PhD, Timothy J Sullivan, Edward Fox, PhD, Scott J. Rodig, MD, PhD, Joseph H Antin, MD, David M Weinstock, MD

Blood (2011) 118 (21): 3671.

https://doi.org/10.1182/blood.V118.21.3671.3671

Published: 2011

Journal Articles

HSP90 Inhibition Targets JAK2 and Is Highly Effective in CRLF2-Rearranged Acute Lymphoblastic Leukemia

Oliver Weigert, MD, Liat Bird, Nadja Kopp, Andrew A. Lane, MD, PhD, Bjoern Chapuy, MD, PhD, Diederik van Bodegom, Sachie Marubayashi, Akinori Yoda, PhD, Vincent Romanet, MSc, Masato Murakami, MD, PhD, Stephen E. Sallan, MD, Ross L Levine, MD, Andrew L. Kung, MD, PhD, Thomas Radimerski, PhD, David M Weinstock, MD

Blood (2011) 118 (21): 576.

https://doi.org/10.1182/blood.V118.21.576.576

Published: 2011

Journal Articles

Genetic Resistance to JAK2 Enzymatic Inhibitors Is Overcome by HSP90 Inhibition

Oliver Weigert, MD, Andrew A. Lane, MD, PhD, Liat Bird, Nadja Kopp, Angela V Toms, Ph.D., Christoph Gaul, Eric Vangrevelinghe, Alain De Pover, Catherine H. Regnier, PhD, Dirk Erdmann, Francesco Hofmann, PhD, Michael Eck, Andrew L. Kung, MD, PhD, Thomas Radimerski, PhD, David M Weinstock, MD

Blood (2011) 118 (21): 62.

https://doi.org/10.1182/blood.V118.21.62.62

Published: 2011

NARROW

HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma

Phenotypic and Transcriptional Characterization of Non-Hodgkin Lymphomas from Malawi Defines Targetable Disease Subsets

B and T-Cell Lymphoma Patient-Derived Xenografts Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development

The MDM2 Inhibitor NVP-CGM097 Is Highly Active in a Randomized Preclinical Trial of B-Cell Acute Lymphoblastic Leukemia Patient Derived Xenografts

Clonal Evolution in Relapsed or Refractory Diffuse Large B Cell Lymphoma

Type II JAK2 Inhibitor NVP-CHZ868 Is Active in Vivo Against JAK2-Dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs)

Newer-Generation HSP90 Inhibitors Can Overcome Ibrutinib Resistance and Suppress Proliferation in Human Mantle Cell Lymphoma in Vitro and in Vivo

GNB1 Activating Mutations Promote Myeloid and Lymphoid Neoplasms Targetable By Combined PI3K/mTOR Inhibition

A targeted mutational landscape of angioimmunoblastic T-cell lymphoma

JAK2 L884P Mutation Confers Resistance To The Type II JAK2 Inhibitor NVP-BBT594 When Co-Occurring With JAK2 R683G But Not JAK2 V617F

The Beta-Subunit Of Heterotrimeric G Proteins Harbors Gain-Of-Function Mutations In Multiple Hematologic Malignancies

Loss-Of-Function Mutations In The Splicing Factor ZRSR2 Are Common In Blastic Plasmacytoid Dendritic Cell Neoplasm and Have Male Predominance

A Targeted Mutational Landscape of Angioimmunoblastic T-Cell Lymphoma: Association Between Advanced Age and Mutations in TET2 and DNMT3A

Newer-Generation HSP90 Inhibitors Have Potent Activity Against Human Mantle Cell Lymphoma in Vitro and in Vivo

BET Bromodomain Inhibition Targets Both c-Myc and IL7R in Acute Lymphoblastic Leukemia

BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia

Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2

Molecular Ontogeny of Donor-Derived Lymphomas Occurring After Transplantation,

HSP90 Inhibition Targets JAK2 and Is Highly Effective in CRLF2-Rearranged Acute Lymphoblastic Leukemia

Genetic Resistance to JAK2 Enzymatic Inhibitors Is Overcome by HSP90 Inhibition

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only